Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in mHSPC

Abroad (travel likely)RecruitingPHASE3

Conditions

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Urology dpt, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Contact: Study coordinator (Shangqian Wang, M.D.,PhD.) · wsq5501@126.com · 68303186
Contact: Principal Investigator (Lixin Hua, M.D.)

Study leads

Lixxin Hua
Principal Investigator
Urology Dpt, First Affiliated Hospital of Nanjing Medical University

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Abroad (travel likely)RecruitingPHASE3

Beijing, China

ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer

Metastatic Castration-resistant Prostate Cancer (mCRPC) · Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Abroad (travel likely)RecruitingPHASE3

Aalst, Belgium · Antwerp, Belgium

A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics

Prostatic Neoplasms · Metastatic Hormone-Sensitive Prostate Cancer

Abroad (travel likely)Recruiting

Cleveland, United States

A Study to Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in France

Prostatic Neoplasms · Metastatic Hormone-sensitive Prostate Cancer

Abroad (travel likely)Recruiting

Caen, France